BioProgress launches new anti-snoring and caffeine products

BioProgress (AIM: BPRG; NASDAQ: BPRG), the speciality pharma and healthcare company is pleased to announce the launch of Ronflux strips, a novel dissolve-in-the-mouth product for the prevention of snoring, and a new range of oral caffeine strips, at Pharmagora 2006.

The products, which will be initially available in France, make use of BioProgress’ novel SOLULEAVES™ technology. This technology allows active ingredients, colours and flavours to be incorporated into a non-genetically modified, non-animal derived film, which dissolves in the mouth, releasing the active ingredients.

The caffeine strips are the first in a new range of products, designed to improve alertness and vitality. The Ronflux strips will tap into the market for medical devices for the treatment of snoring.

The products were launched this weekend (1 April) through BioProgress’ subsidiary Dexo S.A. at Pharmagora 2006, an annual French retail pharmacists’ trade show, this year based at the Paris Expo, Port de Versailles, Paris.

Richard Trevillion, CEO of BioProgress said: “We are pleased to be able to offer these in-the-mouth products that address important needs for improved wellbeing. The launch of two newly-formulated products so soon after the acquisition of Dexo is an excellent validation of the Company’s approach. The launch involved the combined effort of our development teams in Cambridge and Tampa, Florida, USA, our formulation capability, and the sales, marketing and licensing infrastructure, acquired and grown since the Dexo acquisition in January 2006.”

Ronflux is one of the brands that was acquired by BioProgress with the acquisition of Dexo. It is currently marketed as a nasal spray. The newly-formulated products are manufactured at the BioProgress group’s cGMP accredited facility based in Tampa.

BioProgress is currently developing a number of other reformulated products using a variety of the Group’s platform technologies, including TABWRAP™, SWOLLO™ and WAFERTAB™, and containing existing branded and generic formulations.